Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Davis

Emergency Medicine Chester, MT Medical Doctor

NPI 1548204423 CMS profile 24078

315 W Madison Ave, Chester, MT 59522

Open in the dashboard

General payments

$361,238

93 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Davis of Chester, MT is reported in the CMS Open Payments database as having received $361,238 across 93 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,362 9
2024 General $6,951 4
2023 General $630 4
2022 General $122,951 21
2021 General $129,851 20
2020 General $30,997 9
2019 General $50,495 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Davis
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Daniel Davis were reported at $19,362. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Daniel Davis Emergency Medicine median Middle half National median
2019 $50,495 $51 $18–$128 $163
2020 $30,997 $29 $16–$99 $114
2021 $129,851 $40 $18–$124 $132
2022 $122,951 $49 $20–$134 $149
2023 $630 $51 $22–$142 $160
2024 $6,951 $52 $22–$150 $164
2025 $19,362 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Medical Corporation $293,105 58 payments
  2. Philips Electronics North America Corporation $26,139 11 payments
  3. Masimo Corporation $24,000 2 payments
  4. Covidien LP $16,885 13 payments
  5. Stryker Corporation $795 5 payments
  6. Integra LifeSciences Corporation $158 1 payment
  7. Medline Industries, Inc. $128 1 payment
  8. Lilly USA, LLC $16 1 payment
  9. AstraZeneca Pharmaceuticals LP $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $183,485 23 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $95,122 6 payments
  3. Travel and Lodging $41,021 29 payments
  4. Food and Beverage $34,743 31 payments
  5. Honoraria $6,867 4 payments
Products named General payments · program years 2019–2025
  1. AED Service $14,042 3 payments
  2. EMMA and ISA $12,000 1 payment
  3. SedLine $12,000 1 payment
  4. (5132) RDT SV Time Material $6,951 4 payments
  5. RDT SV Time Material $4,811 3 payments
  6. CapnoStream $1,685 4 payments
  7. Smart Capnography $800 1 payment
  8. LIFEPAK 15 MONITOR/DEFIBRILLATOR $630 4 payments
  9. LUCAS $416 2 payments
  10. Tempus Pro Monitor $335 1 payment
  11. Other $822 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,486

Median for Emergency Medicine: 88

Drug cost

$60,818

Median for Emergency Medicine: $590

Branded share of claims

8.1%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 23 $22,546
Eliquis Apixaban Brand 40 $21,326
Farxiga Dapagliflozin Propanediol Brand 12 $4,607
Methenamine Hippurate Generic 20 $1,059
Metoprolol Succinate Generic 58 $873
Potassium Chloride Generic 53 $847
Losartan Potassium Generic 112 $830
Fluticasone Propionate Generic 57 $734
Levothyroxine Sodium Generic 72 $723
Pantoprazole Sodium Generic 57 $506

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$10,910

Medicare's payments for the services billed

Medicare patients

49

Average age 81

Services billed

154

28 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Atrial fibrillation 41%
Chronic kidney disease 39%
Heart failure 37%
Alzheimer's or dementia 37%
Depression 35%
Ischemic heart disease 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

93 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record